← Back to Search

Tyrosine Kinase Inhibitor

TPX-0005 for Tumors

Phase 1 & 2
Waitlist Available
Research Sponsored by Turning Point Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening to end of treatment approximately 10 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called repotrectinib, used together with other cancer treatments. It targets patients whose cancers have a specific genetic mutation called KRAS, which makes their cancer harder to treat. The drug works by blocking signals that help cancer cells grow and spread. Repotrectinib is a new drug being tested for its effectiveness in treating cancers with KRAS mutations, which are known to be challenging to treat.

Eligible Conditions
  • KRAS Mutation-Related Tumors
  • Metastatic Tumor
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening to end of treatment approximately 10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from screening to end of treatment approximately 10 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Dose Limiting Toxicities
Secondary study objectives
AUC 0-24 of Repotrecitinib
AUC 0-24 of Trametinib
Cmax of Repotrectinib
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TPX-0005 + TrametinibExperimental Treatment2 Interventions
TPX-0005 + Trametinib Dose Escalation and Dose Expansion Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trametinib
2014
Completed Phase 2
~1630

Find a Location

Who is running the clinical trial?

Turning Point Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
868 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,569 Previous Clinical Trials
3,384,355 Total Patients Enrolled
8 Trials studying Tumors
422 Patients Enrolled for Tumors
Turning Point Therapeutics, MDStudy DirectorTurning Point Theraperutics
3 Previous Clinical Trials
127 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top